Wound Care Biologics Market Size Worth USD 11.22 Billion By 2034

Major Private Industry Investments in Wound Care Biologics?

North America Wound Care Biologics Market

North America held a significant share of the market in 2024 due to the shift towards advanced wound care, technological advancements, innovative therapies, the rising incidence of traumatic injuries, the increase in chronic injuries, and the growing elderly population in the region. The growing prevalence of chronic disease and rapidly growing aging populations is driving significunt need for advanced wound care biologics.

Countries like the U.S. and Canada are fueling investments in pharmaceutical and biopharmaceutical industries for innovations and developments of comprehensive wound care biologics. Additionally, the presence of a regulatory framework and its approvals for novel innovations are fueling this growth.

What is the U.S. Wound Care Biologics Market Size?

The U.S. wound care biologics market size reached USD 1.96 billion in 2025 and is projected to grow from USD 2.09 billion in 2026 to USD 3.60 billion by 2034, with a CAGR of 6.94% from 2025 to 2034.

U.S. Innovations in the Wound Care Biologics

The U.S. dominating the regional market stems from a confluence of factors, including a large and aging population with a high prevalence of chronic diseases like diabetes and obesity, driving significant demand for advanced wound therapies. This demand is further supported by the U.S.'s high healthcare expenditure, a robust healthcare infrastructure with numerous specialized wound care centers, and a favorable reimbursement system for advanced treatments like biologics.

According to a report published in October 2025, a groundbreaking for a manufacturing facility to develop advanced biologics technology and to bring MedTech jobs to Southern Nevada was announced by Precision Biologics Manufacturing, a New Horizon Medical Solutions (NHMS) company. This center is expanding production of U.S.-based biologics and creating over 200-300 healthcare-centric jobs in the Las Vegas Valley. (Source: )

Asia Pacific Wound Care Biologics Market

The Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period due to strategic agreements, regional market expansion, a focus on developing advanced biologic products, research and development (R&D), and the rising prevalence of chronic wounds in the region. Asia has witnessed rapid expanding in demographic for diabetes.

The growing healthcare infrastructure and rising awareness of cutting-edge wound care solutions among both patients and healthcare professionals are fostering this growth. Additionally, the rapid ongoing innovations in the regenerative medicines are solidifying regional pharmaceutical industries' position across the globe.

Advancements in Medical Technologies: To Boost China's Market

China has dominated the regional market due to its rapidly expanding healthcare infrastructure and growing focus on advanced medical technologies. The country has a large aging population and a rising number of patients suffering from chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which has significantly increased. Government initiatives have played a crucial role in promoting the adoption of biologics in wound management by improving access to healthcare and encouraging the use of innovative treatments.

Wound Care Biologics Market Segmentation Insights:

Wound Type Insights

Why Chronic Wound Dominates the Wound Care Biologics Market?

The chronic wound segment dominated the market in 2024. Wound care biologics like skin substitutes are tissue-engineered products used in the management of chronic non-healing wounds. They can be used either temporarily or permanently to cover the wound bed. These dressings can act to help close chronic wounds and thereby reduce pain and prevent the loss of heat, fluid, protein, and electrolytes. In chronic wounds, innovative bandages target replacing the skin tissue, the dysregulated inflammatory phase, and protect against infection.

• In June 2025, the launch of AdvoGraft One and AdvoGraft Membrane Dual, two biologic wound care products that support natural healing by protecting both acute and chronic wounds, was announced by New Horizon Medical Solutions, a leader in advanced biologics and wound care solutions, through its wholly owned subsidiary, Precise Bioscience, LLC. Both products use processed human placental tissue to better act as a barrier between the wound and the surrounding environment in the healing process. (Source: )
  

The acute wound segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034. In acute wounds, like surgical and traumatic wounds, bandages absorb exudate, inhibit bleeding, and efficiently close wounds to promote healing. Biologics have demonstrated enhanced chronic and acute wound healing rates at a lower total cost than traditional wound care products and demand for products.

Product Insights

Which Product Segment Dominated the Wound Care Biologics Market in 2024?

The biological skin substitutes segment dominated the market in 2024. The biological skin substitutes have the role of permanently achieving wound closure, replacing the skin components, and providing a higher quality skin replacement than the thin autologous skin graft. The biological skin substitutes can allow the construction of a more natural new dermis and enable excellent re-epithelialization features because of the basement membrane.

• In September 2025, the launch of CENTRIO Platelet-Reach-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment, was announced by Smith+Nephew, a global medical technology company. The CENTRIO PRP System helps to manage chronic exuding wounds, including tunneling wounds, pressure ulcers, venous leg ulcers (VLUs), and diabetic foot ulcers (DFUs). (Source: )
  

The topical agents segment is projected to experience the highest growth rate in the market between 2025 and 2034. Topical agents' benefits include takeaways, easy termination, better compliance, easy use, fewer risks of drug abuse, reduced risk of gastrointestinal issues, and an alternative to oral medication. Generally, topical agents are used for nasal or oral bleeding and provide local therapy to the bleeding surface. Topical agents are medications applied directly to the skin to treat many painful conditions.

End User Insights

Which End-user Leads the Wound Care Biologics Market?

The hospitals & clinics segment led the market and is set to experience the fastest rate of market growth from 2025 to 2034. Hospitals & clinics provide medical assistance with innovative treatment facilities. It has made patients' lives simpler through hassle-free health consultations. Hospital management systems centralize and digitize operations, improving efficiency and patient care. They provide valuable data insights, enhance communication among staff, reduce errors, and automate administrative tasks.

The wound centers and burn centers segment is the second-largest segment, leading the market, due to its handling of a high volume of severe, complex wounds and chronic conditions like diabetic foot ulcers and pressure ulcers, which require advanced biologic treatments. These specialized facilities are equipped to manage these cases, providing comprehensive care with specialized equipment, skilled professionals, and continuous treatment crucial for better patient outcomes and higher revenue generation.

You can place an order or ask any questions, please feel free to contact at ... | +1 804 441 9344

Wound Care Biologics Market Top Companies

• Stryker Corporation: This company develops a wide range of orthopaedic biologics, including bone and dermal matrices and viable bone products, that support the body's natural healing processes in various surgical and wound care settings.
• MIMEDX Group, Inc.: As a pioneer in placental biologics, MIMEDX provides a portfolio of products like EPIFIX and EPICORD, which are used to treat chronic and complex wounds by leveraging the regenerative properties of amniotic tissue.
• Lavior Pharma Inc.: Focused exclusively on diabetic skin care, Lavior offers clinically proven, all-natural, botanical-based hydrogel wound dressings that disrupt biofilm and accelerate the healing of diabetic wounds.
• Skye Biologics Holdings, LLC: Skye Biologics develops and commercializes advanced wound care solutions, such as its dehydrated amniotic membrane allografts (e.g., WoundFix), intended for use as wound coverings.
• Integra LifeSciences Holdings Corporation: Integra offers a broad portfolio of tissue-regenerative products, including its proprietary collagen and umbilical tissue matrices, which provide a scaffold for cellular infiltration and the regeneration of dermal tissue.
• ORGANOGENESIS HOLDINGS INC.: This regenerative medicine company provides a comprehensive portfolio of bioactive and acellular biomaterials products for advanced wound care that support the healing process across various wound types.
• ConvaTec Group plc: Following its acquisition of Triad Life Sciences, ConvaTec entered the advanced wound biologics segment with its Innovamatrix products, which use collagen and tissue to treat hard-to-heal wounds.
• Tissue Regenix Group Plc: Using its dCELL technology to create acellular tissue scaffolds from donated human and animal tissue, Tissue Regenix offers products like DermaPure for wound and tissue repair without causing a rejection response.
• Kerecis: Specializing in intact fish skin technology derived from Icelandic cod, Kerecis provides regenerative tissue products that, when grafted onto damaged human tissue, recruit the body's own cells to support regeneration.
• Smith & Nephew plc: This company offers a range of advanced wound management solutions, including advanced bioactive products like STRAVIX umbilical tissue products, which are used for both wound and surgical applications

Recent Developments:

• In May 2025, a free, web-based Wound Assessment App as part of a broader expansion of its mobile wound care services across a 150-mile radius of Houston was introduced by Vital Wound Care. This initiative is enhancing access to wound treatment by delivering care directly to patients' homes, mainly for those with transportation or mobility limitations. (Source: )
  
• According to a report published in April 2025, the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar of Bevacizumab for intravenous use, which was announced by Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd. A recombinant humanized monoclonal antibody, JOBEVNE, is used to treat many different types of cancer, which is biosimilar to the reference product Avastin (bevacizumab). (Source: )
  
• In October 2024, two cutting-edge products for wound care, the Peak Powder Collagen Matrix and the ElectroFiber 3D, were launched by Royal Wound-X, a division of Royal Biologics. Peak Powder Collagen Matrix is a next-generation collagen-based wound care solution that help to improve healing in both surgical and non-surgical wounds. (Source: )
  

Segments Covered in the Report

By Wound Type

• Chronic Wound
• Acute Wound

By Product

• Topical Agents
• Biological Skin Substitutes

By End User

• Hospitals and Clinics
• Wound Centers and Burn Centers
• Others
  

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
  

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

Stay Ahead with Precedence Research Subscriptions

Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve.

Browse Our Subscription Plans@

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web:

Our Trusted Data Partners:

Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor Market Stats Insight

Get Recent News:

/news

For the Latest Update Follow Us:

LinkedIn | Medium | Facebook | Twitter

✚ Related Topics You May Find Useful:

➡️ Advanced Wound Care Market: Explore how innovative dressings, devices, and biologics are redefining chronic wound management and recovery outcomes.

➡️ Anti-Biofilm Wound Dressing Market: Discover how next-generation biofilm-resistant dressings are enhancing infection control and wound healing efficiency.

➡️ Acute Wound Care Market: Understand how emergency and post-surgical care innovations are driving advancements in acute wound treatment.

➡️ Anti-Inflammatory Biologics Market: See how biologic therapies are transforming chronic inflammation management across autoimmune and dermatological conditions.

➡️ Biologics Contract Development Market: Analyze how outsourcing and CDMO partnerships are accelerating biologics innovation and global production capabilities.

➡️ Skin Substitute Market: Learn how bioengineered skin substitutes are revolutionizing treatment for burns, ulcers, and complex wounds.

➡️ Biologics CDMO Market: Track how biologics-focused CDMOs are shaping the future of drug development, scalability, and commercialization.

➡️ Burn Care Centers Market: Examine how specialized care facilities and advanced therapies are improving outcomes for burn patients worldwide.

➡️ Venous Leg Ulcer Market: Gain insight into how advanced wound care and biologic solutions are addressing one of the most persistent vascular complications.